Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB115 in Healthy Volunteers and Pediatric SMA Participants
NCT05575011Phase 1Active, not recruiting
- Sponsor
- Biogen
- Start
- Oct 2022
- Primary completion
- Nov 2031
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 9
01
Overview
Phase 1, randomised, double-blind trial of salanersen in spinal muscular atrophy (SMA) (8 arms), sponsored by Biogen. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 2520. Started Oct 2022; status: active, not recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT05575011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575011.